Kim et al. showed that co-treatment with anti-CTLA-4 and epigenetic-modulating drugs, i.e., 5-AZA and entinostat, a class I HDAC inhibitor, markedly improved treatment outcomes, curing more than 80% of mice bearing colorectal or breast cancers [21]. This evidence concerns the gene CTLA4 and breast carcinoma.